IRCT20190522043669N1CompletedPhase 3
The Effect of Lycopene and FruHis supplementation on serum levels of prostate specific antigen (PSA) and clinical outcomes in Benign Prostate Hyperplasia (BPH) patients
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 50 years to 75 years (—)
- Sex
- Male
Inclusion Criteria
- •Patients with BPH, whose disease is diagnosed by an urologist, range in age from 50 to 75 years.
- •a serum PSA level between 4-10 ng / ml and have a negative DRE test.
- •Negative DRE test.
Exclusion Criteria
- •Use of Finasteride or other anti-androgen drugs for the last 6 months.
- •Prostate cancer and other malignancies such as skin, myeloma and bladder cancers.
- •Chronic diseases such as severe liver disease and renal failure.
- •Bladder and kidney stones.
- •Lycopene supplementation in the last 6 months
- •Any allergies and sensitivities to tomatoes or tomato products
Investigators
Similar Trials
Completed
Phase 1
Checking the effect of lycopene supplement when consumed orally after non-surgical gum therapy.CTRI/2018/02/011759none30
Not yet recruiting
Not Applicable
The advantage of lycopene capsule over cleaning and polishing in smokers having gum problemsCTRI/2020/10/028670Justina David Joy
Recruiting
Not Applicable
Effect of the probiotic strain TENSIA® DSM21380 on high-normal blood pressure and up to grade-1 hypertensioPrehypertensionCirculatory SystemISRCTN51761666BioCC LLC200
Not yet recruiting
Phase 2
Effects of a combination supplement containing Lysine, Vitamin C and Zinc on oxidative stress, glycaemic control and formation of Advanced Glycosylation End Products (AGEs) in patients with type 2 diabetes mellitus: A randomized double-blind, placebo-controlled clinical trialDiabetesSLCTR/2020/020Dr. Jhon Burd
Recruiting
Phase 1
The effect of bioactive compound supplementation on obesity treatmentDiabetes mellitusFatty liverC18.654.726.500C06.552.241C14.907.489C18.452.394.750C18.452.394.968.500ObesityHypertensionInsulin ResistanceRBR-22pqs9Flávia Campos Corgosinho